Other hemorrhagic disorder due to intrinsic circulating anticoagulants, antibodies, or inhibitors
ICD-10 D68.318 is a billable code used to indicate a diagnosis of other hemorrhagic disorder due to intrinsic circulating anticoagulants, antibodies, or inhibitors.
D68.318 refers to a category of hemorrhagic disorders characterized by bleeding due to the presence of intrinsic circulating anticoagulants, antibodies, or inhibitors that interfere with normal coagulation processes. These disorders can manifest as spontaneous bleeding or excessive bleeding following trauma or surgical procedures. The underlying mechanisms often involve the production of autoantibodies that target specific coagulation factors, leading to deficiencies or functional impairments in the coagulation cascade. Conditions such as acquired hemophilia, which is often associated with the presence of inhibitors against factor VIII, fall under this category. Patients may present with symptoms such as easy bruising, prolonged bleeding from cuts, and hemarthrosis. Diagnosis typically involves laboratory tests to assess coagulation factor levels and the presence of inhibitors. Management may include immunosuppressive therapy, factor replacement, and supportive care to control bleeding episodes.
Detailed laboratory results, including specific factor levels and inhibitor testing, along with clinical notes on bleeding episodes.
Patients presenting with unexplained bleeding, history of autoimmune disorders, or previous reactions to anticoagulants.
Ensure that all relevant laboratory tests are documented to support the diagnosis and treatment plan.
Comprehensive patient history, including medication use, family history of bleeding disorders, and detailed physical examination findings.
Patients with chronic conditions that may predispose them to bleeding disorders, such as liver disease or autoimmune conditions.
Document any co-morbid conditions that may affect coagulation status.
Used to evaluate platelet count and overall blood health in patients suspected of having bleeding disorders.
Document the reason for the CBC and any relevant clinical findings.
Hematologists may require additional specific tests based on initial CBC results.
Common symptoms include easy bruising, prolonged bleeding from cuts, spontaneous bleeding, and joint bleeding (hemarthrosis).
Diagnosis typically involves a combination of clinical evaluation, laboratory tests to assess coagulation factor levels, and the presence of inhibitors or antibodies.
Treatment may include immunosuppressive therapy, factor replacement therapy, and supportive care to manage bleeding episodes.
